Novel Anticoagulants for the Prevention and Treatment of Venous Thromboembolism

Wiener Medizinische Wochenschrift

Volumn 153, Issue 19-20, 2003, Pages 426-433

  Weltermann, Ansgar ^a   Kyrle, Paul A ^b   Eichinger, Sabine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticoagulants; Fondaparinux; Heparin; Melagatran; Venous thromboembolism

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9 ANTIBODY; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; INOGATRAN; IPRIVASK; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; MONOCLONAL ANTIBODY 2E9; PLACEBO; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT THROMBOMODULIN; SB 249415; SB 249417; SULODEXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ANTICOAGULATION; AUSTRIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EUROPE; HIP FRACTURE; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNITED STATES; VEIN THROMBOSIS;

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION FACTORS; DRUGS, INVESTIGATIONAL; GLYCINE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; PULMONARY EMBOLISM; RESEARCH; THROMBIN; VENOUS THROMBOSIS; VITAMIN K;

EID: 0242468727     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-003-0030-3     Document Type: Review

References (96)

1. Abendschein DR, Baum PK, Martin DJ, Vergona R, Post J, Rumennik G, Sullivan ME, Eisenberg PR, Light DR: Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol 2000;35:796-805.
2. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247.
3. Agnelli G, Bergqvist D, Cohen A, Gallus A, Gent M: A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus study. J Thromb Haemost 2003; [Suppl 1]:OC006.
4. Andersen K, Dellborg M: Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Am J Cardiol 1998;81:939-944.
5. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933-938.
6. Barritt DW, Jordan SC: Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309-1312.
7. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.
8. Benedict CR, Ryan J, Todd J, Kuwabara K, Tijburg P, Cartwright J Jr, Stern D: Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model. Blood 1993;81:2059-2066.
9. Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D: Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991;88:1760-1765.
10. Bergum PW, Cruikshank A, Maki SL, Kelly CR, Ruf W, Vlasuk GP: Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. J Biol Chem 2001;276:10063-10071.
11. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ: Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-959.
12. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-1489.
13. Cappello M, Vlasuk GP, Bergum PW, Huang S, Hotez PJ: Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci USA 1995;92:6152-6156.
14. Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, Jusko WJ: Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 2002;71:235-245.
15. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V: Venous arm of the SUAVIS (Sulodexide Arterial Venous Italian Study) Group. Randomised, double blind, multicentre, placebo-controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002;87:947-952.
16. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V; Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group: Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J 2002;23:1057-1065.
17. Cohen AT, Gallus AS, Lassen MR, Tomkowski W, Turpie AG, Davidson BL, Cariou RG, Lensing AW, Egberts JF: Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis). J Thromb Haemost 2003; [Suppl 1]:OC006.
18. Cohen AT, Phillips MJ, Edmondson RA, Skinner JA, Das SK, Cooper DJ, Thomas EM, Melissari E, Kakkar VV: A dose-ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty. Thromb Haemost 1994;72: 793-798.
19. Collins R, Scrimgeour A, Yusuf S, Peto R: Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1998;318:1162-1173.
20. Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, Whipple JP, Peters GR, Francis CW: Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism (VTE) after total hip arthroplasty (THA). Blood 2001;98:706a.
21. Comp PC, Voegeli T, McCutchen JW, Skoutakis VA, Trowbridge A, Overdyke WL: A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group. Orthopedics 1998;21:1123-1128.
22. Condorelli M, Chiariello M, Dagianti A, Penco M, Dalla Volta S, Pengo V, Schivazappa L, Mattioli G, Mattioli AV, Brusoni B, et al: IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascularaccidents in the first year after acute myocardial infarction. J Am Coll Cardiol 1994;23:27-34.
23. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S: Additive thrombin inhibition by fast-moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res 2003;109:333-339.
24. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, Hart HC, Sixma JJ, Nieuwenhuis HK: Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995;123:1-9.
25. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL, for the Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003;29:894-903.
26. Di Carlo V, Agnelli G, Prandoni P, Coccheri S, Gensini GF, Gianese F, Mannucci PM: Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. Thromb Haemost 1999;82:30-34.
27. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G: A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.
28. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA: First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002;105:2385-2391.
29. Erhardtsen E, Nilsson P, Johannessen M, Thomsen MS: Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol 2001;41:880-885.
30. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Nylander I, Andersson M: The oral thrombin inhibitor ximelagatran, and its subcutaneous (sc) form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism (VTE) in total hip or total knee replacement (THR or TKR): the EXPRESS study. Blood 2002;100: 82a.
31. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ögren M, on behalf of the METHRO III Study Group: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003;89: 288-296.
32. Eriksson BI, Bauer KA, Lassen MR, Turpie AG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304.
33. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D: Melagatran for Thrombin inhibition in Orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-1447.
34. Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Kalebo P, Close P: Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326-333.
35. Eriksson BI, Lassen MR; for the PENTasaccharide in HIp-FRActure Surgery Plus Investigators: Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337-1342.
36. Eriksson BI, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S, for the THRIVE Investigators: A randomized, controlled, dose-guiding study of oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003;1:41-47.
37. Eriksson BI, Wahlander K, Lundström T, Clason SB, Schulman S, for the THRIVE III Investigators: Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood 2002; 100:81a.
38. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335.
39. Faria F, Kelen EM, Sampaio CA, Bon C, Duval N, Chudzinski-Tavassi AM: A new factor Xa inhibitor (lefaxin) from the Haementeria depressa leech. Thromb Haemost 1999;82:1469-1473.
40. Feuerstein GZ, Toomey JR, Valocik R, Koster P, Patel A, Blackburn MN: An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb Haemost 1999;82:1443-1445.
41. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, Colwell CW Jr: Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR). Blood 2002;100:82a.
42. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW Jr: Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-655.
43. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB: Prevention of venous thromboembolism. Chest 2001;119:1323-1753.
44. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, Jay RM, Leclerc J, Neemeh JA, Turpie AG: Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996;93:80-84.
45. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130: 800-809.
46. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Volpel H, Potzsch B, Luz M: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999;100: 587-593.
47. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R: The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-181.
48. Herbert JM, Bernat A, Dol F, Herault JP, Crepon B, Lormeau JC: DX 9065A a novel, synthetic, selective and orally active inhibitor of factorXa: in vitro and in vivo studies. J Pharmacol Exp Ther 1996;276:1030-1038.
49. Herbert JM, Herault JP, Bernat A, Savi P, Schaeffer P, Driguez PA, Duchaussoy P, Petitou M: SR123781A, a synthetic heparin mimetic. Thromb Haemost 2001;85:852-860.
50. Himber J, Refino CJ, Burcklen L, Roux S, Kirchhofer D: Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb Haemost 2001;85:475-481.
51. Hoek JA, Nurmohamed MT, Hamelynck KJ, Marti RK, Knipscheer HC, ten Cate H, Buller HR, Magnani HN, ten Cate JW: Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992;67:28-32.
52. Howard AW, Aaron SD: Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials. Thromb Haemost 1998;79:902-906.
53. Jacquemin M, Benhida A, Peerlinck K, Desqueper B, Vander Elst L, Lavend'homme R, d'Oiron R, Schwaab R, Bakkus M, Thielemans K, Gilles JG, Vermylen J, Saint-Remy JM: A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000;95:156-163.
54. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D, Wilcox JN: Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992;12:948-954.
55. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-3050.
56. Jilma B, Marsik C, Mayr F, Graninger MT, Taylor FB Jr, Ribel MC, Erhardtsen E, Handler S, Eichler HG: Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002;72:403-410.
57. Kearon C, Comp C, Douketis D, Royds R, Yamada K, Gent M: A dose-response study of recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement. J Thromb Haemost 2003;[Suppl 1]:OC330.
58. Kearon C: Natural history of venous thromboembolism. Circulation 2003;107:122-30.
59. Lassen MR, Bauer KA, Eriksson BI, Turpie AG; for the European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-1720.
60. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS: The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med 1998;158:873-878.
61. Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van Der Meer J, Piovella F, Raskob G, Gent M: Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001;104:74-78.
62. Leger P, Cambus JP, Herault JP, Herbert JM, Boneu B: Antithrombotic effect of a synthetic heparin mimetic in an arterial model of thrombosis in rats: comparison with unfractionated heparin and nadroparin. Thromb Haemost 2002;88:687-688.
63. Lev EI, Marmur JD, Zdravkovic M, Osende JI, Robbins J, Delfin JA, Richard M, Erhardtsen E, Thomsen MS, Lincoff AM, Badimon JJ: Antithrombotic effect of tissue factor inhibition by inactivated Factor VIIa. An ex vivo human study. Arterioscler Thromb Vasc Biol 2002;22:1036-1041.
64. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, for the ARG-911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
65. Magnani HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993;70:554-561.
66. Malkov D, Wang HZ, Dinh S, Gomez-Orellana I: Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. Pharm Res 2002;19:1180-1184.
67. Murayama N, Tanaka M, Kunitada S, Yamada H, Inoue T, Terada Y, Fujita M, Ikeda Y: Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther 1999;66:258-264.
68. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E: Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-156.
69. Persists Investigators: A novel long acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood 2002;100:301a.
70. Peters RJ, Spickler W, Theroux P, White H, Gibson M, Molhoek PG, Anderson HV, Weitz JI, Hirsh J, Weaver WD: Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). Am Heart J 2001;142:237-243.
71. Petitou M, Duchaussoy P, Lederman I, Choay J, Sinay P, Jacquinet JC, Torri G: Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-(1-4)- O-(beta-D-glucopyranosyluronic acid)-(1-4)-O-(2-deoxy-2-sulfamido-3,6-di-O- sulfo-alpha-D-glu copyranosyl)-(1-4)-O-(2-O-sulfo-alpha-L-idopyranosyiuronic acid)-(1-4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr Res 1986;147:221-236.
72. Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM: Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999;398:417-422.
73. Phillips GB, Buckman BO, Davey DD, Eagen KA, Guilford WJ, Hinchman J, Ho E, Koovakkat S, Liang A, Light DR, Mohan R, Ng HP, Post JM, Shaw KJ, Smith D, Subramanyam B, Sullivan ME, Trinh L, Vergona R, Walters J, White K, Whitlow M, Wu S, Xu W, Morrissey MM: Discovery of N-[2-[5-[Amino(imino)methylJ-2- hydroxyphenoxy]-3,5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl) phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J Med Chem 1998;41:3557-3562.
74. Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY: Discovery of 1-[3-(aminomethyl)phenyl] -N-3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenylj-4-yl] -3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2001;44:566-578.
75. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
76. Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, Iverson M, Lim A, Chisholm V, Kelley RF, Riederer M, Kirchhofer D: Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001;85:379-389.
77. Russell D, Kakkar AK, Marder VJ, Pineo GF, Goldberg MM, Raskop GE, for the PROTECT trial: Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement. Blood 2002;100:558a.
78. Samama MM, Gerotziafas GT: Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).Thromb Res 2003;109:1-11.
79. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332: 1661-1665.
80. Singh I, Smith A, Vanzieleghem B, Collen D, Burnand K, Saint-Remy JM, Jacquemin M: Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood 2002;99: 3235-3240.
81. Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM: Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg 1998;115:1179-1188.
82. Taglialatela M: DPC-423 Bristol-Myers Squibb. Curr Opin Investig Drugs 2002;3:252-254.
83. Taniuchi Y, Sakai Y, Hisamichi N, Kayama M, Mano Y, Sato K, Hirayama F, Koshio H, Matsumoto Y, Kawasaki T: Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998;79:543-548.
84. The Matisse Investigators: Fondaparinux (Arixtra) in Comparison to (Low Molecular Weight) Heparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis or Pulmonary Embolism -The Matisse Clinical Outcome Studies. Blood 2002;100:302a.
85. Turpie AG, Bauer KA, Eriksson BI, Lassen MR, for the PENTATHALON 2000 Study Steering Committee: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726.
86. Turpie AG, Bauer KA, Eriksson BI, Lassen MR: Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840.
87. Van Boeckel CA, Petitou M: The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993;32:1671-1690.
88. Van der Heijden JF, Prins MH, Büller HR: Low-molecular-weight heparins: are they interchangeable? Haemostasis 2000;30: 148s-157s.
89. Venosi S, Zamboni V, Irace L, Stumpo R, Massa R, Palazzini E, Valentini FB: Efficacy of an intravenous low-molecular-weight dermatan sulphate (Desmin) in patients with acute proximal deep venous thrombosis and silent pulmonary embolism. A pilot study. J Int Med Res 1997;25:98-107.
90. Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ: Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991;65:257-262.
91. von Kemp K, Jochmans K, van Tussenbroek F, Debruyne H, Van den Brande P: Desmin (a low molecular weight dermatan sulphate) versus heparin in the treatment of patients with deep venous thrombosis. Eur J Clin Pharmacol 1998;54:133-139.
92. Weitz JI, Young E, Johnston M, Stafford AR, Fredenburgh JC, Hirsh J: Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation 1999;99:682-689.
93. Wong AG, Gunn AC, Ku P, Hollenbach SJ, Sinha U: Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis. Thromb Haemost 1997;77: 1143-1147.
94. Wong PC, Pinto DJ, Knabb RM: Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev 2002;20:137-152.
95. Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM: Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 2000;292:351-357.
96. Yang J, Lee GF, Riederer MA, Kelley RF: Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa. Thromb Haemost 2002;87:450-458.